Ahu Senem Demiröz

Dr. Ahu Senem Demiröz


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
SKSerhat Kaymaz
Serhat Kaymaz
SCSelçuk Cin
Selçuk Cin
TETUGRUL ELVERDI
TUGRUL ELVERDI
SASuat Hilal Akı
Suat Hilal Akı
ADAhu Senem Demiröz
Ahu Senem Demiröz
Background: Programmed death-ligand 1 (PD-L1) contributes to immune escape and is a therapeutically relevant target in aggressive B-cell lymphomas. However, its distribution and clinicopathologic significance across primary mediastinal aggressive large B-cell lymphomas remain incompletely defined. Methods: We retrospectively reviewed 53 cases diagnosed between 2010 and 2025, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mediastinal gray zone lymphoma (MGZL), and T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL). PD-L1 immunohistochemistry (clone 22C3) was performed on formalin-fixed, paraffin-embedded tissue. Tumor cells and intratumoral inflammatory cells were assessed together. Membranous staining was scored as 0, 1+, 2+, or 3+, and the proportion of cells in each category was recorded. Results: PD-L1 staining was present in 40/53 cases (75.5%; 95% CI, 61.7–86.2%). Mean PD-L1-positive percentages were similar in DLBCL, PMBCL, and MGZL (38.81%, 31.67%, and 43.89%, respectively; p = 0.726), and no tested cutoff separated the diagnostic groups. In contrast, MGZL showed a higher mean 3+ component (31.11%) and more cases with 3+ staining in at least 50% of evaluated cells (4/9, 44.4%; 95% CI, 13.7–78.8%) than DLBCL (1/21, 4.8%; 95% CI, 0.1–23.8%) or PMBCL (1/21, 4.8%; 95% CI, 0.1–23.8%); the overall comparison remained significant after Bonferroni correction (unadjusted p = 0.012; adjusted p = 0.049). PD-L1 extent was not associated with age, tumor size, LDH, beta-2 microglobulin, Ann Arbor stage, SUVmax, treatment response, or overall survival. Conclusions: PD-L1 expression is common in mediastinal aggressive large B-cell lymphomas. MGZL showed an exploratory strong-staining pattern that requires independent validation. No prognostic association was detected in this cohort.

24 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSerhat Kaymaz
Serhat Kaymaz
SCSelçuk Cin
Selçuk Cin
TETUGRUL ELVERDI
TUGRUL ELVERDI
SASuat Hilal Akı
Suat Hilal Akı
ADAhu Senem Demiröz
Ahu Senem Demiröz
Background: Programmed death-ligand 1 (PD-L1) contributes to immune escape and is a therapeutically relevant target in aggressive B-cell lymphomas. However, its distribution and clinicopathologic significance across primary mediastinal aggressive large B-cell lymphomas remain incompletely defined. Methods: We retrospectively reviewed 53 cases diagnosed between 2010 and 2025, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mediastinal gray zone lymphoma (MGZL), and T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL). PD-L1 immunohistochemistry (clone 22C3) was performed on formalin-fixed, paraffin-embedded tissue. Tumor cells and intratumoral inflammatory cells were assessed together. Membranous staining was scored as 0, 1+, 2+, or 3+, and the proportion of cells in each category was recorded. Results: PD-L1 staining was present in 40/53 cases (75.5%). Mean PD-L1-positive percentages were similar in DLBCL, PMBCL, and MGZL (38%, 36%, and 44%, respectively; p = 0.939), and no tested cutoff separated the diagnostic groups. In contrast, MGZL showed a higher mean 3+ component (31.11%) and more cases with 3+ staining in at least 50% of evaluated cells (44% vs. 4.3% in DLBCL and 4.7% in PMBCL; p = 0.007). PD-L1 extent was not associated with age, tumor size, LDH, beta-2 microglobulin, Ann Arbor stage, SUVmax, treatment response, or overall survival. Conclusions: PD-L1 expression is common in mediastinal aggressive large B-cell lymphomas. MGZL is distinguished by a strong-staining pattern, whereas combined PD-L1 extent was not prognostic in this cohort.

Verified
Journal Article
Open access
PDF file
SCSelçuk Cin
Selçuk Cin
Merve TokoçinMerve Tokoçin
Merve Tokoçin
ÖGÖzgecan Gündoğar
Özgecan Gündoğar
MCMerve Cin
Merve Cin
AMAli Muhammedoğlu
Ali Muhammedoğlu
ADAhu Senem Demiröz
Ahu Senem Demiröz
Background: Pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer is influenced by multiple tumor- and host-related factors, and readily available pretreatment biomarkers of response are still limited. This study aimed to evaluate the association between pretreatment systemic inflammatory and nutritional parameters and pCR assessed by the Miller–Payne grading system, with a specific focus on the independent predictive value of pretreatment serum albumin compared with established inflammatory ratios. Methods: A total of 226 patients with breast carcinoma who received NACT between May 2017 and September 2023 were retrospectively evaluated. Pretreatment laboratory parameters—including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), serum albumin, and the CRP/albumin ratio (CAR)—were recorded. Pathological response was assessed using the Miller–Payne grading system by two breast pathologists blinded to laboratory data. Univariable and multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed, complemented by bootstrap validation of the optimal cut-off, a sensitivity analysis using the contemporary ypT0/is ypN0 definition of pCR, and a subgroup analysis by molecular subtype. Results: pCR was observed in 41 patients (18.1%). Pretreatment serum albumin levels were significantly lower in responders than in non-responders (p = 0.027), whereas NLR, PLR, CRP, and CAR were not significantly associated with response. In multivariable analysis, pretreatment serum albumin, Ki-67, and HER2 status emerged as independent predictors of pCR. ROC analysis demonstrated moderate discriminatory ability for albumin (AUC = 0.64); the optimal cut-off was 4.22 g/dL (bootstrap 95% CI 3.50–4.53 g/dL), with values below this threshold associated with a higher likelihood of pCR. The association between low pretreatment albumin and pCR was particularly pronounced in the triple-negative subgroup (3.30 vs. 4.02 g/dL, p = 0.027). The albumin signal remained significant under the stricter ypT0/is ypN0 definition of pCR in univariable analysis (OR 0.47, p = 0.045). Conclusions: Pretreatment serum albumin, independent of systemic inflammatory ratios, is associated with pCR to NACT in breast cancer and may serve as a candidate biomarker for pretreatment risk stratification, particularly when interpreted alongside established tumor-related predictors such as Ki-67 and HER2 status. The association appears especially relevant in the triple-negative subgroup, suggesting that patients with TNBC and low pretreatment serum albumin may warrant heightened multidisciplinary attention during NACT. Validation in larger, prospective, multicenter cohorts is needed before routine clinical implementation.